Clinical data | |
---|---|
Other names | N,N-Didesmethyl-4,4'-dihydroxytamoxifen |
Identifiers | |
| |
ChemSpider | |
Chemical and physical data | |
Formula | C24H25NO3 |
Molar mass | 375.468 g·mol−1 |
3D model (JSmol) | |
| |
|
4'-Hydroxynorendoxifen is a synthetic, nonsteroidal antiestrogen of the triphenylethylene group.[1][2] It is a dual selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), and was derived from tamoxifen, a SERM, and norendoxifen, a metabolite of tamoxifen that has been found to act as an AI.[1][2] The drug has been suggested for potential development as a treatment for estrogen receptor (ER)-positive breast cancer.[1][2] It was synthesized in 2015.[1]